Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3649917 | 0.87 | PARP10 (0.58) | KMT2AMAPTKDM4ERAB9AEPHX2 | |
| SCHEMBL11307960 | 0.84 | SCN9A (0.49) | KMT2AMAPTKDM4ERAB9ASCN9A | |
| SCHEMBL2545560 | 0.83 | MAPT (0.43) | MAPTKDM4ERAB9ASCN9AEPHX2 | |
| SCHEMBL755015 | 0.83 | MAPT (0.43) | MAPTKDM4ERAB9ASCN9AEPHX2 | |
| SCHEMBL3719026 | 0.81 | MAPT (0.40) | MAPTKDM4ESCN9AHPGDEPHX2 | |
| SCHEMBL2786289 | 0.80 | AR (0.53) | MAPTKDM4ERAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL3727500 | 0.80 | MAPK10 (0.40) | MAPTKDM4ESCN9AHPGDEPHX2 | |
| SCHEMBL79042 | 0.79 | ALDH1A1 (0.50) | KMT2AMAPTKDM4ERAB9ASCN9A | |
| SCHEMBL29638900 | 0.79 | ALDH1A1 (0.50) | KMT2AMAPTKDM4ERAB9ASCN9A | |
| SCHEMBL8116738 | 0.78 | L3MBTL1 (0.47) | KMT2AMAPTKDM4ERAB9AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | KMT2A 3881/4885MAPT 3258/4885KDM4E 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.